IDH1 and central nervous system cancer: Notably, higher levels of CD68-, CD163-, and CD206-positive glioma-associated microglia and macrophages correlate with prolonged survival in IDH1 R132H-non-mutant glioblastoma patients, suggesting that modulation of these immune populations could have therapeutic benefits [32].